Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Ltd has submitted its Annual Report for the financial year 2025-26, along with the notice for its Ninth Annual General Meeting (AGM). The AGM is scheduled for September 25, 2026, at 11:30 AM IST, to be conducted via Video Conferencing. The report includes the Business Responsibility and Sustainability Report. Members will receive the report electronically. Key dates for e-voting are September 18-24, 2026. The annual report details the company's corporate overview, management message, business segments, financials, and ESG commitment, highlighting a 'Positioned for the Next Leap' strategy focusing on organic growth and strategic acquisitions.

Senores Pharmaceuticals Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, as per SEBI Listing Regulations. The report, also available on the company's website, details the company's operations, product/service offerings, and market presence. Senores Pharma, a B2B pharmaceutical developer and manufacturer, reported a turnover of INR 10,609 lakhs and a net worth of INR 74,990 lakhs for the fiscal year. Exports contributed 43.95% to the total turnover. The company operates on a standalone basis for its disclosures and has a grievance redressal mechanism in place for stakeholders.

Senores Pharmaceuticals Ltd has submitted the notice for its 9th Annual General Meeting (AGM) and the Annual Report for the financial year 2025-26. The AGM is scheduled for Friday, September 25, 2026, at 11:30 AM IST, to be conducted via Video Conferencing/Other Audio-Visual Means. The report includes the Business Responsibility and Sustainability Report. The cut-off date for determining e-voting eligibility is September 18, 2026, with remote e-voting open from September 22 to September 24, 2026. The Annual Report details the company's corporate overview, management message, business segments, financials, and ESG commitments, highlighting a strong growth trajectory and expanded market presence.

Senores Pharmaceuticals Limited announced board approvals for key appointments and strategic initiatives. Mrs. Shilpa Sharma has been appointed as Company Secretary and Compliance Officer. Mr. Viranchi Arvindbhai Shah joins as Non-Executive Additional Independent Director. The board also authorized key personnel to determine materiality and make disclosures. Additionally, the company approved the Senores Pharmaceuticals Employee Stock Option Scheme 2026 (ESOS 2026) and the incorporation of a Wholly Owned Subsidiary in Mexico to expand international market presence.

Senores Pharmaceuticals Limited's Board of Directors has approved the proposed incorporation of a wholly-owned subsidiary in Canada to support international business objectives. The board also approved the appointment of Mrs. Shilpa Sharma as Company Secretary and Compliance Officer, and Mr. Viranchi Arvindbhai Shah as Non-Executive Additional Director (Independent Director). Additionally, the company approved the Senores Pharmaceuticals Employee Stock Option Scheme 2026 (ESOS 2026), subject to shareholder and regulatory approvals. Key managerial personnel were also authorized to determine materiality of events and make disclosures.

Senores Pharmaceuticals Limited announced outcomes from its Board Meeting held on August 26, 2026. Key decisions included the appointment of Mrs. Shilpa Sharma as Company Secretary and Compliance Officer, and Mr. Viranchi Arvindbhai Shah as Non-Executive Additional Director (Independent). The Board also approved the Senores Pharmaceuticals Employee Stock Option Scheme 2026 (ESOS 2026), subject to shareholder and regulatory approvals. Furthermore, the company received approval for the incorporation of a Wholly Owned Subsidiary in Mexico to support international market expansion. Authorized officers were appointed to determine materiality of events and make disclosures to stock exchanges.

Senores Pharmaceuticals Limited announced its Board of Directors has approved the incorporation of a wholly-owned subsidiary in Mexico. This strategic move aims to support the company's business operations and growth objectives in the Mexican and broader international markets. The Board also approved the appointment of Mrs. Shilpa Sharma as Company Secretary and Compliance Officer, and Mr. Viranchi Arvindbhai Shah as an Additional Independent Director. Additionally, the Board approved the Senores Pharmaceuticals Employee Stock Option Scheme 2026 (ESOS 2026), subject to shareholder and regulatory approvals. Key managerial personnel were authorized to determine materiality and make disclosures to stock exchanges.

Senores Pharmaceuticals Limited has issued a corporate guarantee of ₹62 Crores for credit facilities availed by its subsidiary, Apnar Pharma Private Limited, from ICICI Bank Limited. The guarantee is effective from August 24, 2026, and will remain valid until the closure of the credit facilities. The promoter and promoter group have an interest in Apnar Pharma through their directorships, and the guarantee is considered to be at arm's length. Currently, the guarantee's impact on Senores Pharmaceuticals is limited to its disclosure as a contingent liability in the financial statements.

Dhananjay Ashokkumar Barot, identified as a Promoter Group member of Senores Pharmaceuticals Limited, has disclosed the disposal of 30,000 equity shares through an off-market inter-se transfer by way of gift. The transaction, which occurred on August 10, 2026, involved no consideration. This transfer is among promoter and promoter group members, thus the aggregate holding of the promoter and promoter group remains unchanged. The disclosure was made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. Senores Pharmaceuticals Limited is listed on both BSE and NSE.

Ashokkumar Vijaysinh Barot has acquired 30,000 equity shares of Senores Pharmaceuticals Limited through an off-market inter-se transfer by way of gift. The transaction occurred on August 10, 2026. This transfer is among promoter and promoter group members, meaning the aggregate holding of the promoter and promoter group remains unchanged. The disclosure was made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The total diluted share capital of the company includes 1,170,000 convertible equity warrants.